Cis-morpholinone MDM2 Inhibitors for Selective p53 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are limited in effectively targeting tumors with p53 wildtype function, as MDM2 inhibitors struggle to selectively activate p53 in normal tissues while inhibiting tumor growth, and existing therapies fail to address the complex interactions between p53 and MDM2.
Innovation Solution
Development of compounds that specifically inhibit the interaction between p53 and MDM2, activating p53 downstream effector genes to treat various cancers, including solid and liquid tumors, by blocking MDM2's mechanisms of p53 inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If MDM2 inhibitors are used to activate p53 in tumor cells, then tumor growth is inhibited, but normal tissues are also affected by mitotic poisons
Solution Approach 1:
The patent applies local quality by designing MDM2 inhibitors with specific molecular structures (Formula I compounds featuring cis-morpholinone core with particular substituent patterns) that preferentially bind to MDM2 in tumor cells where p53 is mutated or overexpressed, thereby activating p53 locally in tumor tissues while sparing normal tissues through selective cellular uptake and binding affinity differences
2Productivity
If existing cancer therapies are applied to tumors with p53 wildtype function, then treatment effectiveness is limited, but alternative approaches are needed
Solution Approach 1:
The patent achieves universality by developing MDM2 inhibitors (Formula I compounds) that can treat multiple types of cancers including those with p53 mutations, p53 amplifications, and p53 wildtype tumors, as well as various solid tumors and liquid tumors, by targeting the conserved MDM2-p53 interaction pathway that is dysregulated across diverse cancer types
Data Source
AI summary
The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.